IP Library Granted Patent US 9,119,829
Granted Patent B2
US 9,119,829 · App. 13/782,421 · Granted Sep 1, 2015

Methods and compositions for delivering interleukin-1 receptor antagonist

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,119,829
App. No.
13/782,421
Granted
Sep 1, 2015
Kind
B2
Abstract

Methods, systems, and compositions related to generating and using a solution rich in interleukin-1 receptor antagonist are provided. Methods include contacting a liquid comprising white blood cells with a solid extraction material and stimulating with an electromagnetic field to activate production of interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist can be separated from the solid extraction material. Methods for treating a site of inflammation in a patient include administering the solution rich in interleukin-1 receptor antagonist to the site of inflammation.

Claims (6)

1. A method for generating a solution rich in interleukin-1 receptor antagonist comprising:

(a) contacting a liquid comprising white blood cells with a solid extraction material, wherein the solid extraction material activates the white blood cells to generate interleukin-1 receptor antagonist, and wherein the solid extraction material comprises a member selected from the group consisting of corundum, quartz, titanium, dextran, agarose, polystyrene, polyethylene, polyvinyl chloride, polypropylene, and combinations thereof;

(b) subjecting the liquid to an electromagnetic field wherein the electromagnetic field comprises a pulsed electromagnetic field or a capacitively coupled electromagnetic field; and

(c) separating the liquid from the solid extraction material to obtain a solution rich in interleukin-1 receptor antagonist, wherein the concentration of interleukin-1 receptor antagonist in the solution is greater than the concentration of interleukin-1 receptor antagonist in the liquid prior to contacting the liquid with the solid extraction material.

2. The method according to claim 1 , wherein the contacting the liquid comprising white blood cells with the solid extraction material and the subjecting the liquid to the electromagnetic field are performed in less than 1 hour.

3. The method according to claim 1 , wherein the liquid comprising white blood cells comprises whole blood, bone marrow aspirate, adipose tissue, fractions thereof, and mixtures thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2018
From: BIOMET BIOLOGICS, LLC
To: BIOMET, INC.
Reel/Frame 045914/0262 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2018
From: ZB MANUFACTURING, LLC
To: BIOMET MANUFACTURING, LLC
Reel/Frame 045914/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2018
From: BIOMET, INC.
To: ZB MANUFACTURING, LLC
Reel/Frame 045914/0350 →